CDSCO Panel Recommends Protocol Amendment for Novartis' Ianalumab Trial Farhat Nasim21 May 2025 8:03 PM ISTNew Delhi: The Subject Expert Committee (SEC) on Haematology, functional under the Central Drugs Standard Control Organisation (CDSCO) has recommended...
CDSCO Panel Approves Novartis' Protocol Amendment proposal for Iptacopan Clinical study in Kidney Disorders Dr. Divya Colin10 May 2025 6:00 PM ISTNew Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the proposal...
Novartis executive Ramon Zapata-Gomez to join BioNTech as CFO Ruchika Sharma6 May 2025 3:30 PM ISTGermany: BioNTech SE has announced that the Supervisory Board has appointed Ramon Zapata-Gomez to the Management Board as Chief Financial...
Novartis to acquire kidney disease drug maker Regulus Therapeutics for up to 1.7 billion Ruchika Sharma1 May 2025 12:30 PM ISTTransaction includes USD 0.8 billion upfront with a potential additional USD 0.9 billion payment upon the achievement of a future regulatory...
Novartis plans to invest USD 23 billion over next 5 years in US based infrastructure Ruchika Sharma13 April 2025 12:30 PM ISTEast Hanover: Novartis, a global medicines company, has announced a planned USD 23 billion investment over 5 years in US-based infrastructure,...
FDA Grants Accelerated Approval to Atrasentan for IgA Nephropathy Dr. Kamal Kant Kohli5 April 2025 9:30 AM ISTThe US FDA has granted accelerated approval to atrasentan (Vanrafia) for reducing proteinuria in adults with primary immunoglobulin A (IgA)...
Novartis receives USFDA accelerated approval for Vanrafia for proteinuria reduction in primary IgA nephropathy Ruchika Sharma3 April 2025 4:30 PM ISTEast Hanover: Novartis has received accelerated approval from the US Food and Drug Administration (FDA) for Vanrafia...
Novartis appoints Karen Hale as Chief Legal and Compliance Officer Ruchika Sharma31 March 2025 2:55 PM ISTBasel: Novartis has announced the appointment of Karen Hale to the expanded role of Chief Legal and Compliance Officer for Novartis, effective...
Novartis radioligand therapy Pluvicto gets USFDA nod for expanded indication Ruchika Sharma29 March 2025 1:15 PM ISTBasel: Novartis has announced that the US Food and Drug Administration (FDA) has approved Pluvicto (lutetium Lu 177 vipivotide tetraxetan) for...
Novartis oral Fabhalta secures USFDA okay for adults with C3 glomerulopathy Ruchika Sharma21 March 2025 12:42 PM ISTBasel: Novartis has announced that the U.S. Food and Drug Administration (FDA) has approved oral Fabhalta (iptacopan) for the treatment...
CDSCO Panel Approves Updated Package Insert for Novartis' Ofatumumab Injection Dr. Divya Colin16 March 2025 5:45 PM ISTNew Delhi:The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the proposal...
Novartis Gets CDSCO Panel Nod To Study Antiparasitic drug LXE408 Dr. Divya Colin7 March 2025 5:15 PM ISTNew Delhi: Drug major Novartis has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control...
